For Patients & Visitors

Find a Doctor

Search Doctors

Dr Soon Yu Yang

Tel:

+65 6773 7888

Email:

ncis@nuhs.edu.sg

URL:

http://www.ncis.com.sg

Designations:

Consultant, Department of Radiation Oncology, National University Cancer Institute, Singapore

Qualifications:

BSc (Pharmacy) (Hons) (S'pore), MBBS (Hons) (Sydney), MSc (Clinical Epidemiology) (Harvard), FRANZCR (Radiation Oncology)

Specialties:

Radiation Oncology

Special Interests:

Clinical Trials, Evidence Synthesis, Clinical Epidemiology

Make an Appointment

Biosketch

Dr Soon is a radiation oncologist who specialises in thoracic and lower gastrointestinal malignancies.

After undergoing radiation oncology training at the National University Cancer Institute, Singapore and Peter MacCallum Cancer Centre, Australia, he was awarded the Thomas Baker Fellowship from the Royal Australian New Zealand College of Radiologists to pursue a Masters of Science in Clinical Epidemiology at the Harvard University.

His research is focused on improving health outcomes for those affected by cancer using contemporary clinical trials and evidence synthesis methodologies. He was awarded the NMRC Research Training Fellowship to pursue a PhD in clinical trial methodology at the NHMRC Clinical Trial Centre at the University of Sydney in 2022. He is a Deputy Chair of the lung working party for the Trans Tasman Radiation Oncology Group, and serves as the Co-Chair of OUTRUN, an international randomised trial evaluating the role of stereotactic radiosurgery in EGFR mutant non-small cell lung cancer with brain metastases treated with Osimertinib. He is the faculty of the Australia and Asia Pacific Oncology Research Development Workshop that teaches early career cancer researchers on developing a clinical trial protocol.

Journals & Publications

Selected Publications

1. Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, Sundar R, Soon YY. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022 Mar 2;376:e068632. doi: 10.1136/bmj-2021-068632.

2. Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, Smyth EC, Soon YY, Sundar R. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. J Clin Oncol. 2022 Feb 1;40(4):392-402. doi: 10.1200/JCO.21.01862.

3. Soon YY, Zheng H, Ho SZ, Koh WY, Leong CN, Tey JCS, Vellayappan B, Yap SP, Tham IWK, Fong KW. Adoption of prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (ES-SCLC): a population based outcome study. Radiat Oncol. 2018 Dec 14;13(1):247. doi: 10.1186/s13014-018-1184-x.

4. Soon YY, Leong CN, Koh WY, Tham IW. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.

Radiother Oncol. 2015 Feb;114(2):167-72. doi: 10.1016/j.radonc.2014.12.011.

5. Soon YY, Tham IW, Lim KH, Koh WY, Lu JJ. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev. 2014 Mar 1;2014(3):CD009454. doi: 10.1002/14651858.CD009454.pub2.

6. Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2011 Feb 1;29(4):456-63. doi: 10.1200/JCO.2010.30.2174.

7. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009 Jul 10;27(20):3277-83. doi: 10.1200/JCO.2008.19.4522.

Best viewed with IE 11, Chrome 79.0, Firefox 61.0, Safari 11

2022/04/22